Management Team

Robert Shovlin
President & Chief Executive Officer
Mr. Shovlin is CEO of Aureon Laboratories.  Mr. Shovlin joined Aureon Laboratories in June of 2005 as Vice President of Sales and Marketing. Prior to joining Aureon, he was the Executive Director of anatomic pathology for Quest Diagnostics Incorporated (NYSE: DGX), a $5 billion clinical laboratory. In this role he had national responsibility for Quest Diagnostics’ $500 million anatomic pathology business. Mr. Shovlin also previously held a regional sales director position managing $1 billion of health plan customer business for Quest Diagnostics. Before working at Quest Diagnostics, he held several sales and sales management roles at DIANON Systems, Inc. a $200 million specialty anatomic pathology laboratory. Robert is a former Captain in the United States Marine Corps who holds a B.S. from Penn State University and an M.B.A. from Rutgers University.

Robert L. Van Nostrand
Executive Vice President & Chief Financial Officer
Mr. Van Nostrand joined Aureon Laboratories in January 2010.  Prior to joining Aureon, he served as Executive Vice President and Chief Financial Officer at AGI Dermatics, Inc.  Prior to his tenure at AGI Dermatics, Mr. Van Nostrand spent 21 years at OSI Pharmaceuticals, Inc., where he served as Senior Vice President, and Chief Compliance Officer, among other positions.  Mr. Van Nostrand remains an active board member for Metabolix, Inc., Achillion Pharmaceuticals, Inc. and is affiliated with numerous organizations including the Association of Biofinance Officers, the New York Biotechnology Association, the Cold Spring Harbor DNA Learning Center Corporate Advisory Board and the Foundation Board of Farmingdale University. Mr. Van Nostrand is a certified public accountant and holds a B.S. in Accounting from Long Island University. He has also completed Advanced Management Studies at The Wharton School.

Ricardo Mesa-Tejada, M.D.
Vice President, Pathology & Medical Director
Dr. Mesa-Tejada joined Aureon Laboratories in 2006 as VP of Pathology and Medical Director. Prior to joining Aureon, Dr. Mesa-Tejada trained in anatomic pathology at the College of Physicians and Surgeons of Columbia University where he served as full-time faculty for ten years and presently holds a part-time appointment as Associate Clinical Professor. While primarily engaged in breast cancer research at Columbia, his emphasis on the use immunologic and molecular tissue localization techniques led to his recruitment by MetPath Laboratories, presently Quest Diagnostics, where he founded and directed the Molecular Tissue Pathology Laboratory at its Teterboro, NJ headquarters for ten years. Dr. Mesa-Tejada has been a member of several NIH/NCI scientific review panels and presently serves on the Medical Advisory Board of the Norma F. Phriem Breast Care Center, Fairfield/Bridgeport, CT, and the Boards of the Society for Applied Immunohistochemistry and American Fertility Services, New York, NY. Prior to joining Aureon, he was a consultant to several specialty pathology laboratories and biotechnology companies, and was Senior VP - Health Sciences at Thieme Consulting, Inc., the consulting branch of Thieme Associates, a New York-based global financial services group.

Charles J. DiComo, Ph.D.
Vice President of Operations
Dr. DiComo has been with Aureon since its inception in 2001 as its Senior Scientist, Head of Operations and recently Director of Laboratories. He was instrumental in the site search, the original design and build-out of the corporate offices and CLIA-certified / CAP-accredited clinical laboratories, including the company’s Prognostic/Diagnostic Services and R&D facilities. Dr. DiComo is currently Aureon's VP of Operations overseeing day-to-day commercial operations, sales and customer support, corporate compliance and the intellectual property portfolio.

Prior to joining Aureon, Dr. DiComo was Laboratory Head/Research Associate in the Division of Molecular Pathology at Memorial Sloan-Kettering Cancer Center as a Leukemia and Lymphoma Society Research Special Fellow. In this capacity, Dr. DiComo managed and coordinated day-to-day operations of the molecular and histopathology laboratories, assisted in the scientific direction of post-doctoral fellows, graduate students, and technicians, conducted independent research as part of the New York p53 Consortium, and developed state-of-the-art molecular pathology methodologies in conjunction with Dr. Carlos Cordon-Cardo. Prior to MSKCC, Dr. DiComo was a Damon Runyon-Walter Winchell Fellow at Columbia University in the Department of Biological Sciences with Dr. Carol Prives. Dr. DiComo completed his graduate studies at Cold Spring Harbor Laboratories through a joint program with the University of New York at Stony Brook. His work has been published in numerous peer-reviewed journals, such as Clinical Cancer Research, Oncogene and Cell. Charles holds a B.S. in Molecular and Cellular Biology and an M.S. in molecular and cellular genetics from Long Island University – C.W. Post Campus, as well as a Ph.D. in Genetics from the State University of New York at Stony Brook.